This observation strongly suggests that a specific inhibitor of Kir6.1/SUR2B may offer new therapeutic opportunities for treating PDA and potentially other cardiovascular complications observed in Cantu syndrome. Here, KCNJ8 is linked to Patent ductus arteriosus.